To further explore the effects of differential CD8+ immune cell infiltration in the GBM tumor microenvironment, we performed a longitudinal evaluation of immunotherapy response while monitoring via [89Zr]-CD8 ImmunoPET imaging one- and three-weeks post treatment. The gene discussed is CD8A; the disease is glioblastoma.